Group 1 - The core point of the article is that XinNuoWei (300765.SZ) announced that its subsidiary, Jushi Biotech, received approval from the National Medical Products Administration for the clinical trial of SYS6023, a HER3-targeted antibody-drug conjugate for use in patients with unresectable locally advanced or metastatic breast cancer [1] Group 2 - SYS6023 utilizes a topoisomerase I inhibitor developed by the company as its payload [1] - The approval allows the company to conduct clinical trials, which are necessary before the drug can be marketed and sold, following further regulatory approval [1] - The drug development process is characterized by high investment, high risk, and long cycles, with potential risks including underperformance in clinical trials, failure to obtain regulatory approval, delays in market launch, or lower-than-expected sales post-launch [1]

Core Viewpoint - The recent leadership change at Newnoway, with a young manager taking over amidst significant financial losses, highlights the challenges faced by Chinese pharmaceutical companies in their transformation efforts [1][15]. Management Changes - Newnoway appointed Dai Long, a 1992-born executive, as the new general manager, who previously served as the board secretary and will also continue as the financial director [1][17]. - The former general manager, Yao Bing, will remain as the chairman [17]. - Dai Long's annual salary is only 223,200 yuan despite holding multiple positions, reflecting the company's current financial constraints [5][19]. Financial Performance - Newnoway expects a net loss of 170 million to 255 million yuan for 2025, marking a decline of 416% to 575% compared to the previous year, which will be the company's first annual loss since its listing in 2019 [15][20]. - The company's net profit dropped from 726 million yuan in 2022 to 43.4 million yuan in 2023, a decrease of 40.18%, and further to 5.37 million yuan in 2024, a decline of 87.63% [6][20]. - The decline in performance is attributed to increased R&D expenses, expanded losses from acquired subsidiaries, and decreased gross margins in traditional business lines [20][21]. Business Transformation - Newnoway is transitioning from traditional functional raw materials, primarily caffeine, to innovative pharmaceuticals, including antibody-drug conjugates and mRNA vaccines [10][24]. - The company acquired a 51% stake in Giant Stone Biotech in 2023 and increased its stake to 80% in 2025, but the subsidiary has not yet contributed positively to overall performance [10][24]. - The strategic partnership with AstraZeneca, potentially worth over $17 billion, offers a glimmer of hope for the company's innovative drug pipeline [12][25]. Challenges and Outlook - Newnoway faces the challenge of balancing its declining traditional business with the need for substantial investment in innovative drug development [13][25]. - As of the third quarter of 2025, the company's debt ratio rose to 32.94%, indicating increased financial pressure [13][25]. - The success of Dai Long's leadership will be critical in navigating these challenges and achieving a successful transition from a traditional raw material supplier to an innovative pharmaceutical company [26][27].

Core Viewpoint - The company, XinNuoWei, is expected to report a significant loss of between 170 million to 255 million yuan for the year 2025, marking a year-on-year decline of 416% to 575% due to increased R&D investments and challenges in transitioning from traditional raw materials to innovative pharmaceuticals [1] Group 1: Financial Performance - In 2022, XinNuoWei achieved peak performance with revenue and net profit attributable to shareholders of 2.626 billion yuan and 726 million yuan, respectively [4] - Revenue for 2023 and 2024 is projected to decline to 2.539 billion yuan and 1.981 billion yuan, with net profit dropping to 434 million yuan and 53.73 million yuan [4] - The company anticipates a significant loss in 2025 primarily due to a drop in vitamin B12 prices and increased competition in the caffeine business [5] Group 2: Business Transition and R&D - XinNuoWei is in a critical transition phase from traditional raw material business to innovative pharmaceuticals, having acquired an 80% stake in Giant Stone Bio, a subsidiary focused on ADC, mRNA vaccines, and antibody therapies [3] - The company has increased its R&D expenditure to approximately 1 billion yuan in 2025, reflecting a substantial year-on-year growth, which is a key factor affecting current profits [1] - Several products have made significant progress, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals in 2025 [1] Group 3: Market Position and Challenges - XinNuoWei remains a leading global producer of synthetic caffeine, maintaining a strong market share and serving major clients like Coca-Cola, Pepsi, and Red Bull [2] - The profitability of the traditional core business has declined due to market factors, impacting the overall profit from functional raw materials [2] - The company faced challenges in its vitamin business, with a lack of growth in traditional health products and new business lines not yet achieving scale [5]

Core Viewpoint - The company Shiyao Group's subsidiary, Shiyao Innovation Pharmaceutical, forecasts a significant net loss for 2025, with expected losses ranging from 170 million to 255 million yuan, marking a decline of 416% to 575% compared to the previous year [1][4]. Financial Performance Summary - The net profit attributable to shareholders is projected to be a loss of 170 million to 255 million yuan, compared to a profit of 53.73 million yuan in the same period last year, representing a decline of 416% to 575% [2][5]. - The net profit after deducting non-recurring gains and losses is expected to be a loss of 210 million to 315 million yuan, down from a profit of 42.34 million yuan in the previous year, indicating a decline of 596% to 844% [2][5]. Reasons for Performance Changes - The company has made significant progress with multiple research and development (R&D) products, leading to increased R&D expenses. The total R&D expenditure is expected to reach approximately 1 billion yuan, reflecting a substantial increase year-on-year [3][5]. - The acquisition of an additional 29% minority stake in the subsidiary, Jushi Bio, has increased its ownership to 80%. Jushi Bio is currently not profitable due to high R&D investments, and the increased stake has amplified its impact on the consolidated financial statements [6]. - The company's functional raw materials business has experienced a decline in profit due to reduced gross margins on caffeine products, despite efforts to increase sales [7].

Group 1 - The core viewpoint of the article indicates that Shiyao Group's subsidiary, Shiyao Innovation, is expected to report a net loss attributable to shareholders of 170 million to 255 million yuan for the fiscal year 2025, compared to a profit of 53.7263 million yuan in the previous year [1] - The expected net loss after deducting non-recurring gains and losses is projected to be between 210 million and 315 million yuan, with the previous year's profit being 42.3419 million yuan [1] - The increase in research and development (R&D) expenses to approximately 1 billion yuan, a significant year-on-year increase, is a major factor affecting the current period's profit [1] Group 2 - In early November 2025, Shiyao Innovation completed the acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotech, raising its ownership to 80% [2] - Due to significant investments in the research pipeline, Jushi Biotech is currently not profitable, and the increased ownership will amplify its impact on the consolidated financial statements of the company [2] - The company is actively consolidating its advantage in the functional raw materials business, particularly in caffeine products, although the gross margin and profitability of these products have slightly declined compared to the same period last year due to market factors [2]

Core Viewpoint - XinNuoWei (300765) is expected to report a net profit attributable to shareholders of between -170 million to -255 million yuan for the year 2025, indicating a shift from profit to loss year-on-year [1] Group 1: Financial Performance - The company anticipates a significant decline in profitability for 2025, with a projected net loss compared to previous earnings [1] - The expected net loss range for 2025 is between -170 million to -255 million yuan [1] Group 2: Business Operations - In early November 2025, the company completed the acquisition of an additional 29% minority stake in its subsidiary, JuShi Bio, increasing its ownership to 80% [1] - JuShi Bio is currently not profitable due to substantial investments in its research pipeline, which will further impact the company's consolidated financial statements as the ownership stake increases [1]

Core Viewpoint - The company, Shiyao Group, is expected to report a significant net loss for its subsidiary, Shiyao Innovation, in 2025, contrasting with a profit in the previous year, primarily due to increased R&D investments and operational challenges [1][2]. Group 1: Financial Performance - Shiyao Innovation anticipates a net loss attributable to shareholders of 170 million to 255 million yuan for 2025, compared to a profit of 53.7263 million yuan in the previous year [1]. - The expected net loss, excluding non-recurring items, is projected to be between 210 million and 315 million yuan, down from a profit of 42.3419 million yuan in the prior year [1]. Group 2: R&D Investments - The company is significantly increasing its R&D expenditures, with total R&D costs expected to rise to approximately 1 billion yuan, marking a substantial year-on-year increase [1]. - Several products in the pipeline have made important progress, including four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1]. Group 3: Subsidiary Developments - In early November 2025, Shiyao Innovation completed the acquisition of an additional 29% minority stake in its subsidiary, Jushi Biotech, raising its ownership to 80% [2]. - The increased stake in Jushi Biotech, which is currently not profitable due to high R&D investments, will have a more pronounced impact on the consolidated financial statements of Shiyao Innovation [2]. Group 4: Functional Raw Materials Business - Shiyao Innovation is working to strengthen its position in the functional raw materials sector, particularly in caffeine products, although the gross margin and profitability of these products have slightly declined compared to the previous year due to market factors [2].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致之任何損失承擔任何責任。 CSPC PHARMACEUTICAL GROUP LIMITED 石 藥 集 團 有 限 公 司 （股份代號：1093） （於香港註冊成立之有限公司） 石藥創新製藥股份有限公司 截至2025年12月31日止年度之業績預告 按深圳證券交易所之相關規定，石藥集團有限公司（「本公司」）之附屬公司石藥創新製藥股份 有限公司（「石藥創新」，其股份於深圳證券交易所創業板市場上市（ 股票代碼：300765）），已 於2026年1月15日發佈其截至2025年12月31日止年度之業績預告公告（「業績預告公告」）於深 圳證券交易所網站資訊披露頁面http:// www.szse.cn/ disclosure/listed/ notice/index.html。 本公司及董事會全體成員保證信息披露的內容真實、準確、完整，沒有虛假記載、誤導 性陳述或重大遺漏。 本公告附錄（「附錄」）所載由石藥創新根據中國企業會計準則編製之業 ...

Core Viewpoint - The company expects a loss of 170 million to 255 million yuan in 2025, with a non-recurring loss of 210 million to 315 million yuan, primarily due to increased R&D investments to accelerate its innovation pipeline [1] Group 1: Financial Performance - The company anticipates a significant increase in R&D expenses, projected to reach approximately 1 billion yuan, which is a substantial year-on-year growth and a key factor affecting current profits [1] - The company completed the acquisition of an additional 29% minority stake in its subsidiary, Giant Stone Biotechnology, raising its ownership to 80%, which will increase the impact of Giant Stone's losses on the consolidated financial statements [1] Group 2: R&D Progress - During the reporting period, multiple products in the pipeline made significant progress, with four antibody drugs, six ADC products, and one mRNA vaccine receiving clinical trial approvals for the first time in 2025 [1] - One monoclonal antibody product (Omarizumab injection) received approval for a new indication, while another monoclonal antibody product (Pertuzumab injection) had its listing application accepted; additionally, two ADC products entered Phase III clinical trials [1] Group 3: Business Operations - The company is actively consolidating its competitive position in the functional raw materials business, particularly by increasing sales of caffeine products [1] - However, due to market factors, the gross margin and profitability of caffeine products slightly declined compared to the same period last year, leading to a decrease in profits from the functional raw materials business [1]

石药集团(01093)早盘涨近5%，截至发稿，涨4.79%，报7.88港元，成交额3.96亿港元。 消息面上，12月10日，石药创新首次向港交所递交招股书，拟在香港主板上市。公开资料显示，石药创 新由石药集团分拆而来，已于2019年3月在A股上市，A股简称为新诺威（300765）。若此次港股上市成 功，石药创新将成为又一家"A+H"两地上市的医药企业。 公开资料显示，2023年，石药创新完成企业名称变更，由新诺威正式更名为石药创新。次年又掏出 18.71亿元以增资方式完成对其"兄弟公司"巨石生物51%股权的收购，成为该公司的控股股东，正式将业 务链实质性延伸至生物创新药领域。此次石药创新赴港上市旨在通过外部融资减缓资金压力，支撑创新 药业务发展。 ...